Premium
TCG Lifesciences Pvt. Ltd, a part of The Chatterjee Group, may record a weaker performance for the year ended March 2024 due to losses incurred by its subsidiaries but is likely to bounce back in the ongoing financial year. The contract research and informatics services company’s standalone revenue for FY24 is ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
